Arbutus Biopharma Corp (ABUS) Overview
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $3.65
- Previous close
- $4.69
- Change
- -$1.04
- Change (%)
- -22.17%
- Close date
- 2026-11-06
- Previous close date
- 2026-09-29
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- ABUS
- -2.49%
- S&P 500
- (m)
1 year
- ABUS
- +5.16%
- S&P 500
- (m)
3 years
- ABUS
- +131.03%
- S&P 500
- (m)
5 years
- ABUS
- +9.84%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
CAD / share · As filed
(m)
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|
31 Dec 2012 ○ Estimate (m) ● Actual 2.08
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2012 | 31 Dec 2012 | (m) | 2.08 | (m) | (m) |
| 1 Jan 2011 | 31 Dec 2011 | (m) | -0.88 | (m) | (m) |
| 1 Jan 2010 | 31 Dec 2010 | (m) | -1.20 | (m) | (m) |
USD / share · As filed
30 Jun 2026 ○ Estimate (m) ● Actual -0.03
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Apr 2026 | 30 Jun 2026 | (m) | -0.03 | (m) | (m) |
| 1 Jan 2026 | 31 Mar 2026 | (m) | 0.87 | (m) | (m) |
| 1 Jul 2025 | 30 Sept 2025 | (m) | -0.04 | (m) | (m) |
| 1 Apr 2025 | 30 Jun 2025 | (m) | 0.01 | (m) | (m) |
| 1 Jan 2025 | 31 Mar 2025 | (m) | -0.13 | (m) | (m) |
31 Dec 2025 ○ Estimate (m) ● Actual -0.17
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2025 | 31 Dec 2025 | (m) | -0.17 | (m) | (m) |
| 1 Jan 2024 | 31 Dec 2024 | (m) | -0.38 | (m) | (m) |
| 1 Jan 2023 | 31 Dec 2023 | (m) | -0.44 | (m) | (m) |
| 1 Jan 2022 | 31 Dec 2022 | (m) | -0.46 | (m) | (m) |
| 1 Jan 2021 | 31 Dec 2021 | (m) | -0.83 | (m) | (m) |
(m)
Revenue vs. Earnings
CAD
No complete retained periods.
31 Dec 2012 ■ Revenue 14.11M ■ Earnings 29.79M — Profit margin 211.19%
Revenue vs. Earnings
USD
30 Jun 2026 ■ Revenue 1.01M ■ Earnings -5.14M — Profit margin -507.20%
31 Dec 2025 ■ Revenue 14.08M ■ Earnings -33.50M — Profit margin -237.88%
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $3.65 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning ABUS
View more →(m)
Statistics
View more →Retained observations as of 2026-11-11; financial period ending (m).
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- (m)
- Profit margin
- (m)
- Return on assets · 12 month
- (m)
- Stock compensation expense · all employees · 12 months
- (m)
- Named executive and board stock awards · latest fiscal year
- (m)
- Index membership
- (m)
- Employees
- (m)
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 6.42M
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- -6.39%*
- Total return · month
- -7.50%*
- Total return · quarter
- 0.21%*
- Total return · half year
- 9.32%*
- Total return · year to date
- -2.49%*
- Total return · 1 year
- 5.16%*
- Total return · 3 years
- 131.03%*
- Total return · 5 years
- 9.84%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- Revenue · 12 month
- (m)
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- (m)
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
Arbutus Biopharma Corp Overview
View more →(m)
(m)
- SEC CIK
- 1447028
- Industry (SIC)
- 2834 Pharmaceutical Preparations
- Country of operation
- United States
- Business address
- 701 VETERANS CIRCLE, WARMINSTER, Pennsylvania, 18974, United States
- Fiscal year end
- 1231
- Phone
- 604-419-3200
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |